Share on StockTwits

Equities researchers at Gabelli started coverage on shares of Achaogen (NASDAQ:AKAO) in a research report issued on Friday. The firm set a “hold” rating on the stock.

Achaogen (NASDAQ:AKAO) opened at 15.40 on Friday. Achaogen has a one year low of $11.66 and a one year high of $19.69. The stock has a 50-day moving average of $13.94 and a 200-day moving average of $14.56. The company’s market cap is $272.3 million.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.00) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.48) by $0.52. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $5.39 million. Analysts expect that Achaogen will post $-1.34 EPS for the current fiscal year.

AKAO has been the subject of a number of other recent research reports. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Achaogen in a research note on Tuesday, April 8th. They now have a $22.00 price target on the stock. Finally, analysts at William Blair initiated coverage on shares of Achaogen in a research note on Monday, April 7th. They set an “outperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $22.50.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of antibacterials to treat multi-drug resistant (NASDAQ:AKAO), gram-negative infections.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.